EU Widens Probe Into Suicide Risks Linked to Weight-Loss Drugs.

(Bloomberg) -- The European Union's drug regulator expanded its investigation into a possible risk of suicidal thoughts associated with a new class of weight-loss drugs after receiving 150 reports. The European Medicines Agency is looking at all drugs known as GLP-1 receptor agonists after initially focusing on side effects linked to Novo Nordisk A/S's Wegovy, Ozempic and Saxenda, the agency said in a statement Tuesday. [Extracted from the article]